key: cord-0946391-dd9h1ib6
authors: Linares, M.; Perez Tanoira, R.; Romanyk, J.; Perez Garcia, F.; Gomez-Herruz, P.; Arroyo, T.; Cuadros, J.
title: Panbio antigen rapid test is reliable to diagnose SARS-CoV-2 infection in the first 7 days after the onset of symptoms
date: 2020-09-23
journal: nan
DOI: 10.1101/2020.09.20.20198192
sha: 47f78721e161bb061a2e698c969cbdab32618d73
doc_id: 946391
cord_uid: dd9h1ib6

Background: Real-time reverse transcription polymerase chain reaction (RT-qPCR) is the current recommended laboratory method to diagnose SARS-CoV-2 acute infection, several factors such as requirement of special equipment, time consuming, high cost and skilled staff limit the use of these time-consuming molecular techniques. A more rapid and high-throughput method is in growing demand Methods: Evaluate the performances of the Panbio COVID-19 AG Rapid Test Device (Nasopharyngeal), a rapid immunochromatographic test for the detection of SARS-CoV-2 antigen, in comparison to RT-qPCR. Results: The RDT evaluated in this study showed a high sensitivity and specificity in samples mainly obtained during the first week of symptoms and with high viral loads. Conclusions: This assay seems to be an effective strategy for controlling the COVID-19 pandemic for the rapid identification and isolation of SARS-CoV-2 infected patients.

Ensuring accurate diagnosis is essential to limit the spread of SARS-CoV-2 and for the clinical management of COVID-19. Although real-time reverse transcription polymerase chain reaction (RT-qPCR) is the current recommended laboratory method to diagnose SARS-CoV-2 acute infection, several factors such as requirement of special equipment, time consuming, high cost and skilled staff limit the use of these molecular techniques. A more rapid and high-throughput method is in growing demand. (1, 2) Until now, the use of antigen detection tests alone had been ruled out and not recommended due to their low sensitivity (3) (4) (5) . Previously in the first wave, several easy to perform rapid antigen detection tests were developed as the first line of diagnostic. However, the results obtained were not good enough. (6) (7) (8) (9) Material and methods

Study was conducted between September 10, 2020 and September 15, 2020. We included patients that were attended at our emergency department and in two of our primary healthcare centers:

Emergency department (ED) patients: we included 135 symptomatic patients that were admitted in our ED with clinical suspicion or COVID-19 and 17 asymptomatic patients with history of contact with another COVID-19 patient.

Primary healthcare (PH) patients: 50 symptomatic patients and 55 asymptomatic patients attendend in two of our primary healthcare centres. A total of two consecutive nasopharyngeal swabs were obtained from each patient. One of them was employed to perform the antigenic rapid test and the other sample was employed to carry out the RT-PCR.

RT-PCR: one automatic extractor was employed to obtain viral RNA from clinical samples: Hamilton Microlab Starlet (Hamilton Company, Bonaduz, Switzerland). RNA amplification was made using Allplex SARS-CoV-2 assay (Seegene, Seoul, South Korea).

Antigenic rapid test: we applied the Panbio COVID-19 Ag Rapid Test Device (Abbott Rapid Diagnostic Jena GmbH, Jena, Germany). This test is a qualitative membrane-based immunoassay (immunochromatography) for the detection of Nucleocapsid protein of SARS-CoV-2 in nasopharyngeal samples.

Demographic (age and sex) and clinical variables of the study population were obtained from the medical records. We also recorded the time from the onset of symptoms and the story of prior contact with COVID-19 patients.

Specificity and sensitivity with 95% confidence intervals (95%CI) were calculated using the RT-PCR results as gold standard. Sensitivity was evaluated globally and also according to the time from the onset of symptoms (< 7 days and > 7 days). Additionally, we also calculated the negative predictive value (NPV) and positive predictive value (PPV) for estimated prevalence of infection of 1%, 2.5%, 5% and 10%. Agreement between techniques was evaluated using Cohen's kappa score. (10) . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 23, 2020. . Continuous variables were presented as median and interquartile range (IQR) and categorical variables as proportions. We used the Mann-Whitney U-test, χ2 test, or Fisher's exact test to compare differences between survivors and non-survivors where appropriate. For these comparisons, a p value of 0.05 or below was considered significant. Statistical analysis was performed with SPSS v20.0 (IBM Corp., Armonk, NY, USA). is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 23, 2020. . 255 nasopharyngeal swabs collected from symptomatic and asymptomatic patients were tested. 60 (23,5%) positive RT-qPCR samples, 44 (17,2%) were detected by the rapid antigen test. Overall, amongst the 60 positive samples, the Ct value was detected for gene N in 53 samples. The COVID-19 Ag detected 43 samples (81.1%) ( Table 3 ). The range of cycle threshold (Ct) values was 10.84-37.65 (median 22.32 IQR 18.31-29.02). For samples with Ct < 25 (n = 33), <30 (n = 7), <35 (n = 2) and <40 (n=1), COVID-19 Ag has a sensitivity of 100%, 87.5%, 25% and 25% respectively. However, in our study population, the overall sensitivity is 73.3% (95% IC: 62.2-83.8). Considering only symptomatic patients with less of seven days since onset, the sensitivity is 86.5% (95% IC: 75.0-97.0). Specificity is always 100%.

The RDT evaluated in this study showed a high sensitivity and specificity in samples mainly obtained during the first week of symptoms and with high viral loads (table 2) is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 23, 2020. . Figure 1 . COVID-19 antigen results according to viral load.

As of September 18, 2020, the Food and Drug Administration (FDA) has approved more tan 150 SARS-CoV-2 RNA detection kits. (11, 12) The lateral flow assay (LFA) is user-friendly, cheap, and easily mass-produced. In addition, it may be the optimal method for in-field detection of SARS-CoV-2 antigens if accurate, easy-to-use, rapid, and cost-effective. (13) Our results suggest that Panbio™ COVID-19 AG Rapid Test Device can rapidly identify SARS-CoV-2-infected individuals with moderate to high viral loads. Antigenic tests have shown 100% specificity in all types of patients and can be a powerful tool of high positive predictive value to control the COVID pandemia. It could be used as a substitute technique for PCR in this type of patients to shortcut delays and intensive labour costs generated by the massive use of PCRs.

In the group of symptomatic patients with less than 7 days of evolution, the test reaches a sensitivity of 86,5%, low to that described in the technical data sheet of the test. It is necessary to carry out studies with more patients to assess the usefulness that this technique could have in evaluating the infective potential of close contacts with PCR positive patients (14, 15) . When testing with antigen tests, it must be considered that the infection prevalence and the clinical context of the recipient of the test affects at the pretest probability of the result being correct. Also, rapid antigen tests could be used for screening in high-risk clusters settings to identify quickly persons with a SARS-CoV-2 infection and prevent the transmission by repeat testing. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 23, 2020. . https://doi.org/10.1101/2020.09.20.20198192 doi: medRxiv preprint

Laboratory diagnosis of emerging human coronavirus infectionsthe state of the art

Comparison of Commercially Available and Laboratory-Developed Assays for In Vitro Detection of SARS-CoV-2 in Clinical Laboratories

COVID-19) Update: FDA Authorizes First Antigen Test to Help in the Rapid Detection of the Virus that Causes COVID-19 in Patients

Low performance of rapid antigen detection test as frontline testing for COVID-19 diagnosis

Clinical Evaluation of Self-Collected Saliva by Quantitative Reverse Transcription-PCR (RT-qPCR), Direct RT-qPCR, Reverse Transcription-Loop-Mediated Isothermal Amplification, and a Rapid Antigen Test To Diagnose COVID-19

Recent Advances and Emerging Trends

Development, characterization, and application of monoclonal antibodies against severe acute respiratory syndrome coronavirus nucleocapsid protein Clin

Proposal of De Novo Antigen Test for COVID-19: Ultrasensitive Detection of Spike Proteins of SARS-CoV-2. Diagnostics (Basel)

Evaluation of rapid antigen test for detection of SARS-CoV-2 virus

Interrater reliability: the kappa statistic

COVID-19) Emergency Use Authorizations for Medical Devices

Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection

Discontinuation of Transmission-Based Precautions and Disposition of Patients with COVID-19 in Healthcare Settings (Interim Guidance)

Duration of Isolation and Precautions for Adults with COVID-19